ICANDRA
Informació principal
- Denominació comercial:
- ICANDRA 1000/50 mg 60 comprimidos recubiertos
- ingredients actius:
- metformina+vildagliptina
- Codi ATC:
- A10BD
- Designació comuna internacional (DCI):
- metformin+vildagliptina
- formulario farmacéutico:
- Comprimidos
- Vía de administración:
- Oral
- Utilitza per:
- Humans
- Tipo de medicina:
- medicament al·lopàtic
Documents
- per al públic en general:
- Prospecte
-
- per als professionals de la salut:
- El prospecte d'informació d'aquest producte no està disponible actualment, pot enviar una petició al nostre servei al client i li notificarem tan aviat com ens sigui possible per aconseguir-ho.
Sol·licitar el prospecte d'informació per als professionals sanitaris.
Localització
- Disponible en:
-
Andorra
- Idioma:
- català
Altres dades
Estat
- Font:
- CedimCat - Centre d'Informació de Medicaments de Catalunya
- Número d'autorització:
- 662083
- última actualització:
- 09-06-2018
Prospecte: composició, indicacions, interacció, posologia, embaràs, lactància, reaccions adverses
ICANDRA 1000/50 mg 60 comprimidos
recubiertos
metformina+vildagliptina
Indicacions
Medicament que s'utilitza per tractar la diabetis (ANTIDIAB
TIC) i que actua disminuint el sucre
(GLUCOSA) en sang.
Consideracions
NO prengui aquest medicament si
s al
rgic a METFORMINA.
Prengui els comprimits sencers, sense partir ni mastegar, empassant-los amb ajuda d'un got d'aigua.
Prengui aquest medicament amb els menjars o amb algun aliment per tal d'evitar possibles mol
sties
d'est
mac.
Segueixi estrictament la pauta indicada pel seu metge pel que fa a dosi i freq
眉猫
ncia d'administraci
Avisi el seu metge si pateix o ha patit problemes de cor, problemes de rony
, problemes de fetge o
problemes respiratoris.
Aquest medicament modifica l'acci
d'altres f
rmacs, NO prengui altres medicaments sense consultar
abans al seu metge o farmac
utic.
s possible que el seu metge li recomani una dieta especial, que conv
seguir per augmentar l'efic
cia d'aquest medicament.
NO begui alcohol mentre duri el tractament, perqu
poden augmentar els efectes adversos.
Si t
una "baixada de sucre" pot apar
ixer suor freda, somnol
ncia i debilitat. Prengui
immediatament alguna subst
ncia ensucrada i comuniqui-li-ho al seu metge.
Si t
una "pujada de sucre" pot apar
ixer set intensa i gran quantitat d'orina. Si aquests s
mptomes
persisteixen, digui-li-ho al seu metge.
Per tal de controlar l'efecte d'aquest medicament pot ser necessari que li facin an
lisi de sang;
important que no oblidi anar al metge els dies que li hagin indicat.
Informi immediatament el seu metge si est
embarassada o creu que pot estar-ho, aix
com si qued
s embarassada durant el tractament.
Avisi al seu metge si t
algun fill a qui estigui alletant.
Efectes adversos
Aquest medicament pot produir n
usees, tremolors, mal de cap i mareigs.
Si not
s qualsevol altre s
mptoma que creu que pot ser causat per aquest medicament, digui-li-ho al
seu metge.
Posologia
Prengui 1 comprimit a l'esmorzar i al sopar.
VIA ORAL.
- L'accés a aquest document només està disponible per a usuaris registrats.
Fes-ara per tenir accés complet
3-8-2018
Human medicines European public assessment report (EPAR): Jentadueto, linagliptin / metformin hydrochloride, Revision: 14, Authorised
Europe - EMA - European Medicines Agency
3-8-2018
Human medicines European public assessment report (EPAR): Ristfor, sitagliptin / metformin hydrochloride, Revision: 18, Authorised
Europe - EMA - European Medicines Agency
1-8-2018
Human medicines European public assessment report (EPAR): Janumet, sitagliptin / metformin, Revision: 23, Authorised
Europe - EMA - European Medicines Agency
31-7-2018
Human medicines European public assessment report (EPAR): Velmetia, sitagliptin / metformin, Revision: 25, Authorised
Europe - EMA - European Medicines Agency
3-7-2018
Human medicines European public assessment report (EPAR): Velmetia, sitagliptin / metformin, Revision: 24, Authorised
Europe - EMA - European Medicines Agency
3-7-2018
Human medicines European public assessment report (EPAR): Janumet, sitagliptin / metformin, Revision: 22, Authorised
Europe - EMA - European Medicines Agency
2-7-2018
Human medicines European public assessment report (EPAR): Ristfor, sitagliptin / metformin hydrochloride, Revision: 17, Authorised
Europe - EMA - European Medicines Agency
2-7-2018
Human medicines European public assessment report (EPAR): Efficib, sitagliptin / metformin, Revision: 23, Authorised
Europe - EMA - European Medicines Agency
27-6-2018
Human medicines European public assessment report (EPAR): Synjardy, empagliflozin / metformin, Revision: 13, Authorised
Europe - EMA - European Medicines Agency
19-6-2018
Opinion/decision on a Paediatric investigation plan (PIP): -, Dapagliflozin / saxagliptin / metformin (hydrochloride), Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
Europe - EFSA - European Food Safety Authority EFSA Journal
19-6-2018
Opinion/decision on a Paediatric investigation plan (PIP): -, dapagliflozin / metformin (hydrochloride), Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
Europe - EFSA - European Food Safety Authority EFSA Journal
31-5-2018
Human medicines European public assessment report (EPAR): Eucreas, vildagliptin / metformin, Revision: 17, Authorised
Europe - EMA - European Medicines Agency
23-5-2018
Human medicines European public assessment report (EPAR): Segluromet, ertugliflozin / metformin hydrochloride, Revision: 1, Authorised
Europe - EMA - European Medicines Agency
18-5-2018
Human medicines European public assessment report (EPAR): Vokanamet, canagliflozin / metformin, Revision: 11, Authorised
Europe - EMA - European Medicines Agency
14-5-2018
Human medicines European public assessment report (EPAR): Velmetia, sitagliptin / metformin, Revision: 23, Authorised
Europe - EMA - European Medicines Agency
14-5-2018
Human medicines European public assessment report (EPAR): Ristfor, sitagliptin / metformin hydrochloride, Revision: 16, Authorised
Europe - EMA - European Medicines Agency
8-5-2018
Human medicines European public assessment report (EPAR): Efficib, sitagliptin / metformin, Revision: 22, Authorised
Europe - EMA - European Medicines Agency
4-5-2018
Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin / metformin, Revision: 17, Authorised
Europe - EMA - European Medicines Agency
12-12-2018
Metformin: List of nationally authorised medicinal products - PSUSA/00002001/201804
Metformin: List of nationally authorised medicinal products - PSUSA/00002001/201804
Europe - EMA - European Medicines Agency
14-11-2018
Ebymect (AstraZeneca AB)
Ebymect (Active substance: dapagliflozin / metformin) - Centralised - 2-Monthly update - Commission Decision (2018)7605 of Wed, 14 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4162/WS/1380
Europe -DG Health and Food Safety
2-10-2018
Xigduo (AstraZeneca AB)
Xigduo (Active substance: dapagliflozin/metformin) - Centralised - Renewal - Commission Decision (2018)6462 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2672/R/44
Europe -DG Health and Food Safety
15-8-2018
Komboglyze (AstraZeneca AB)
Komboglyze (Active substance: saxagliptin / metformin) - Centralised - 2-Monthly update - Commission Decision (2018)5559 of Wed, 15 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2059/WS/1289
Europe -DG Health and Food Safety
30-7-2018
Segluromet (Merck Sharp and Dohme B.V.)
Segluromet (Active substance: ertugliflozin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5103 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4314/T/2
Europe -DG Health and Food Safety
3-7-2018
Efficib (Merck Sharp and Dohme B.V.)
Efficib (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4254 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/896/T/90
Europe -DG Health and Food Safety
3-7-2018
Ristfor (Merck Sharp and Dohme B.V.)
Ristfor (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4249 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1235/T/77
Europe -DG Health and Food Safety
3-7-2018
Velmetia (Merck Sharp and Dohme B.V.)
Velmetia (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4252 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/862/T/93
Europe -DG Health and Food Safety
3-7-2018
Janumet (Merck Sharp and Dohme B.V.)
Janumet (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4251 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/861/T/90
Europe -DG Health and Food Safety
30-5-2018
Vokanamet (Janssen-Cilag International NV)
Vokanamet (Active substance: canagliflozin / metformin hydrochloride) - Centralised - Yearly update - Commission Decision (2018)3463 of Wed, 30 May 2018
Europe -DG Health and Food Safety
28-5-2018
Vipdomet (Takeda Pharma A/S)
Vipdomet (Active substance: alogliptin / metformin) - Centralised - Renewal - Commission Decision (2018)3346 of Mon, 28 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2654/R/24
Europe -DG Health and Food Safety
24-5-2018
Velmetia (Merck Sharp and Dohme Limited)
Velmetia (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3261 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708
Europe -DG Health and Food Safety
24-5-2018
Ristfor (Merck Sharp and Dohme Limited)
Ristfor (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3262 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708
Europe -DG Health and Food Safety
24-5-2018
Janumet (Merck Sharp and Dohme Limited)
Janumet (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3260 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708
Europe -DG Health and Food Safety
24-5-2018
Efficib (Merck Sharp and Dohme Limited)
Efficib (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3276 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708
Europe -DG Health and Food Safety